Search research articles
Contact Us
Filters
Showing results (51-60 of 81) with videos related to
Page
of 9
Sort By:
Blood Advances
|
March 20, 2023
Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence
Rory M Shallis, Rong Wang, Amer M Zeidan, et al.
Cancer Medicine
|
February 13, 2024
Real-world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia
Scott F Huntington, Enrico de Nigris, Justin T Puckett, et al.
JCO Oncology Practice
|
December 20, 2024
Real-World Treatment Patterns After Discontinuation of Venetoclax or BTKis in the Frontline Setting Among Older Adults With Chronic Lymphocytic Leukemia
Scott F Huntington, Joanna M Rhodes, Beenish S Manzoor, et al.
Cancer
|
September 5, 2019
Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population-level analysis
Amer M Zeidan, Nikolai A Podoltsev, Xiaoyi Wang, et al.
Blood Neoplasia
|
November 11, 2025
Second malignancies among older patients with classical myeloproliferative neoplasms treated with ruxolitinib
Rong Wang, Jessica M Stempel, Rory M Shallis, et al.
JNCI Cancer Spectrum
|
July 31, 2019
Association Between Ownership of Imaging Equipment and Appropriateness of Staging Positron-Emission Tomography in Non-Hodgkin Lymphoma
Scott F Huntington, Weiwei Zhu, Jessica R Hoag, et al.
Cancer
|
September 15, 2018
Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma
Scott F Huntington, Jessica R Hoag, Weiwei Zhu, et al.
Leukemia & Lymphoma
|
October 2, 2019
Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents
Amer M Zeidan, Xin Hu, Weiwei Zhu, et al.
Leukemia & Lymphoma
|
November 19, 2024
Cost-effectiveness of Enasidenib versus conventional care for older patients with <i>IDH2-</i>mutant refractory/relapsed AML
Abdulrahman Alhajahjeh, Kishan K Patel, Rory M Shallis, et al.
Blood Advances
|
May 21, 2020
Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States
Amer M Zeidan, Rong Wang, Xiaoyi Wang, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 81) with videos related to
Sort By:
Page
of 9
Blood Advances
|
March 20, 2023
Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence
Rory M Shallis, Rong Wang, Amer M Zeidan, et al.
Cancer Medicine
|
February 13, 2024
Real-world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia
Scott F Huntington, Enrico de Nigris, Justin T Puckett, et al.
JCO Oncology Practice
|
December 20, 2024
Real-World Treatment Patterns After Discontinuation of Venetoclax or BTKis in the Frontline Setting Among Older Adults With Chronic Lymphocytic Leukemia
Scott F Huntington, Joanna M Rhodes, Beenish S Manzoor, et al.
Cancer
|
September 5, 2019
Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population-level analysis
Amer M Zeidan, Nikolai A Podoltsev, Xiaoyi Wang, et al.
Blood Neoplasia
|
November 11, 2025
Second malignancies among older patients with classical myeloproliferative neoplasms treated with ruxolitinib
Rong Wang, Jessica M Stempel, Rory M Shallis, et al.
JNCI Cancer Spectrum
|
July 31, 2019
Association Between Ownership of Imaging Equipment and Appropriateness of Staging Positron-Emission Tomography in Non-Hodgkin Lymphoma
Scott F Huntington, Weiwei Zhu, Jessica R Hoag, et al.
Cancer
|
September 15, 2018
Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma
Scott F Huntington, Jessica R Hoag, Weiwei Zhu, et al.
Leukemia & Lymphoma
|
October 2, 2019
Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents
Amer M Zeidan, Xin Hu, Weiwei Zhu, et al.
Leukemia & Lymphoma
|
November 19, 2024
Cost-effectiveness of Enasidenib versus conventional care for older patients with <i>IDH2-</i>mutant refractory/relapsed AML
Abdulrahman Alhajahjeh, Kishan K Patel, Rory M Shallis, et al.
Blood Advances
|
May 21, 2020
Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States
Amer M Zeidan, Rong Wang, Xiaoyi Wang, et al.
Page
of 9